AstraZeneca vs Meta: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Meta side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

3. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

4. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

5. 2004Meta

   Facebook launches at Harvard

   Facebook launched on February 4, 2004, as a real-name student network. The product mattered because it made identity, campus trust and friend connections the core of the service before the company became a public social platform.

6. 2006AstraZeneca

   Acquisition of Cambridge Antibody Technology

   AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

7. 2007AstraZeneca

   Acquisition of MedImmune for $15.6 Billion

   AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

8. 2007Meta

   Ad platform becomes the business model

   Facebook's advertising products turned user attention into a scalable commercial system. The shift mattered because the company could keep the consumer product free while charging marketers for measurable reach, targeting and conversion tools.

9. 2012AstraZeneca

   Pascal Soriot Appointed CEO

   Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

10. 2012Meta

    Instagram acquisition

    Facebook agreed to acquire Instagram for about $1 billion in cash and stock. The deal mattered because Instagram was mobile-native at a moment when Facebook needed to prove it could survive the smartphone shift.

11. 2012Meta

    Facebook IPO

    Facebook completed its initial public offering in May 2012, raising about $16 billion.

12. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

13. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

14. 2014Meta

    WhatsApp acquisition

    Facebook announced a deal to acquire WhatsApp, adding a large private messaging network to a company still known mainly for public feeds.

15. 2014Meta

    Oculus acquisition

    Facebook agreed to acquire Oculus VR for about $2 billion. The deal mattered because it gave the company a hardware and immersive-computing bet years before the Meta rebrand.

16. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

17. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

18. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

19. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

20. 2021Meta

    Facebook becomes Meta

    Facebook changed its corporate name to Meta in 2021 to bring its apps and technologies under a new company brand.

21. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

22. 2023Meta

    Threads launch

    Meta launched Threads in July 2023 and said the app passed 100 million sign-ups in its first five days. The launch mattered because Instagram distribution gave Meta a fast entry into real-time text conversation.

23. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

24. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

25. 2024Meta

    $164.501B revenue

    Meta reported $164.501 billion in FY2024 revenue and $62.360 billion in net income. The year mattered because AI-powered ad tools, Reels monetization and expense discipline restored confidence after the 2022 slowdown.

26. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

27. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

28. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

29. 2025Meta

    $200.966B Revenue

    Meta reported $200.966B in FY2025 revenue, $60.458B in net income, $83.276B in income from operations, and 78,865 employees at year-end.

30. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

31. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

32. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

33. 2026Meta

    Q2 2026 revenue up 28%

    Meta reported Q2 2026 revenue of $60.80B, up 28%, and net income of $15.85B, down 14%, after $2.40B of legal charges and $1.18B of severance from a May 2026 headcount reduction. It narrowed 2026 capex guidance to $130-145B.

Acquisitions

Questions about AstraZeneca vs Meta